ReVeRA-301
Multi-Center, Multi-National, Placebo-Controlled, Phase 3 Study of Etripamil Nasal Spray (NS) in Patients with Atrial Fibrillation and Rapid Ventricular Rate (RVR)
- Stadium
- inclusie
- Middel
- Etripamil
- Populatie
- Ritme
- Fase
- III
- First Patient In
- 1 september 2026
- Last Patient In
- 1 september 2028
- Last Patient Last Visit
- -
Inclusieperiode, nog 712 dagen over
Studiedirecteur
dr. A.M.W. Alings
Cardioloog
Contact Kantoor
